Sun Pharmaceutical Industries has entered into a collaboration with China Medical System Holdings (CMS) to develop and commercialize seven undisclosed generic products in mainland China. The agreement with the Chinese sales and marketing specialist builds on deals announced in late June this year whereby the Indian firm exclusively licensed to CMS two speciality products, the novel psoriasis treatment Ilumya (tildrakizumab) and Cequa (cyclosporine A) 0.09% eye drops, for marketing in Greater China.
“This collaboration gives us entry into the Chinese generic pharmaceutical market,” commented Sun’s managing director Dilip Shanghvi